Epitomee Medical Ltd (EPIT) Fair Value & Analysis
Healthcare · Il · Market cap 72.1M ILA · ISIN IL0011825911
Strengths
Risks
Fair value as of: Aug 28, 2026
From 1 valuation models · updated today
Fair value updated Aug 28, 2026, revised from 5.50 ILA to 5.43 ILA (−1.3%) since Aug 20, 2026. Share price −29.1% over the past month.
Below-average quality, trading 56% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (31/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (4.06 ILA). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (4.06 ILA to 8.11 ILA) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
56‑month range 2.40 ILA – 40.93 ILA · fair‑value band 4.06 ILA – 8.11 ILA · the 2.40 ILA price screens below the 5.43 ILA fair value. Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Epitomee Medical Ltd (EPIT) currently trades at 2.40 ILA, while our model-based Fair Value estimate is 5.43 ILA, implying the stock looks roughly 126.1% undervalued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
It earns a return on equity of -28.8%. The balance sheet holds a net cash position of 25.8M ILA. Fundamentals as of Aug 28, 2026
Our scenario range runs from 4.06 ILA (bear case) to 8.11 ILA (bull case); at 2.40 ILA, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 126%, EPIT screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when EPIT reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Epitomee Medical Ltd reported revenue of $735K in FY2025 versus $0 in FY2021. Reported net income was −$29.7M in FY2025.
Watch EPIT: get an alert when its fair value changes →
Peer Group
Medical Devices · 364 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $114.10 | $74.79 | -34% |
| Stryker Corporation SYK | $329.67 | $186.28 | -43% |
| Medtronic plc MDT | $92.02 | $65.57 | -29% |
| Boston Scientific Corporation BSX | $48.17 | $30.73 | -36% |
| Edwards Lifesciences Corporation EW | $90.78 | $41.02 | -55% |
| Siemens Healthineers AG SHL | €39.26 | €33.87 | -14% |
| DexCom, Inc DXCM | $88.96 | $38.95 | -56% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare Epitomee Medical Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Epitomee Medical Ltd (EPIT) overvalued or undervalued?
What is the fair value of EPIT?
What is the quality score of EPIT?
What is the net profit margin of EPIT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Epitomee Medical Ltd in the live analysis
One click puts Epitomee Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.